ViatrisVTRS
About: Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Employees: 32,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
58% more call options, than puts
Call options by funds: $40.9M | Put options by funds: $25.9M
10% less first-time investments, than exits
New positions opened: 109 | Existing positions closed: 121
3.14% less ownership
Funds ownership: 83.41% [Q4 2024] → 80.26% (-3.14%) [Q1 2025]
3% less funds holding
Funds holding: 1,015 [Q4 2024] → 982 (-33) [Q1 2025]
21% less repeat investments, than reductions
Existing positions increased: 293 | Existing positions reduced: 369
33% less capital invested
Capital invested by funds: $12.4B [Q4 2024] → $8.34B (-$4.05B) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 14 [Q4 2024] → 7 (-7) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Goldman Sachs Matt Dellatorre | 10%upside $10 | Neutral Initiated | 6 Jun 2025 |
Financial journalist opinion
Based on 3 articles about VTRS published over the past 30 days
